NCT03595917
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
At risk: Primary completion moved 7 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 14 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Nov 1, 2026 to Jun 1, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 59 words
- Enrollment closed, study ongoing
- Final enrollment: 65 participants (planned 40)
- Site details revised at 4 of 4 sites
- Notable Primary completion date: Nov 1, 2025 to Nov 1, 2026
- Study completion date: Nov 1, 2026 to Nov 1, 2027
- Minor Site details revised at 1 of 4 sitesv13
- Notable Primary completion date: Nov 1, 2023 to Nov 1, 2025
- Study completion date: Nov 1, 2024 to Nov 1, 2026
- Site details revised at 1 of 4 sites
- Minor Site details revised at 1 of 4 sitesv11
Show 8 earlier versionsHide 8 earlier versions
Notable Trial status: Active, Not Recruiting to Recruitingv10 Show 6 more changesShow less
- Eligibility criteria expanded, about 135 words
- Enrollment target: 34 to 40
- Interventions: ABL001 (Drug), Dasatinib (Drug), Prednisone (Drug) to ABL001 (Drug), Blinatumomab (Drug), Dasatinib (Drug), Prednisone (Drug)
- Study description revised
- Site details revised at 4 of 4 sites
- Study title expanded, about 2 words
- Notable Lead sponsor: Marlise R. Luskin to Marlise Luskin, MD
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 6 to 4
- Minor Study sites: 5 to 6v8
- Notable Primary completion date: Nov 1, 2021 to Nov 1, 2023v7
- Minor Study sites: 3 to 5v6
- Notable Primary completion date: Nov 1, 2019 to Nov 1, 2021
- Study sites: 1 to 3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jul 2018 to Jul 24, 2018
- Site details revised
- Study Identification, Study Status, Sponsor/Collaboratorsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
\- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D) * Dasatinib-Fixed doses oral once a day per cycle * ABL001 is administered orally daily per cycle * Prednisone-Fixed doses oral once a day per cycle. \--- Prednisone will be tapered and stop during cycle 2. * Blinatumomab - intravenous continuous infusion beginning no earlier than cycle 2 day 1 * Blinatumomab - Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
Drugs: ABL001, Dasatinib, Prednisone, Blinatumomab
Sites
4 sites in 1 country